Dynamic Cardiovascular Risk Assessment in Elderly People. The Role of Repeated N-Terminal Pro-B-Type Natriuretic Peptide Testing

Journal of the American College of Cardiology

Volumn 55, Issue 5, 2010, Pages 441-450

  deFilippi, Christopher R ^a   Christenson, Robert H ^a   Gottdiener, John S ^a   Kop, Willem J ^a   Seliger, Stephen L ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

biomarkers; elderly; heart failure; risk stratification

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

AGED; AGING; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM EXAMINATION; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; GERIATRICS; HEART DEATH; HEART FAILURE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; BIOLOGICAL MARKERS; FEMALE; HEART FAILURE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 74549154441     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.07.069     Document Type: Article

References (34)

1. Schocken D.D., Arrieta M.I., Leaverton P.E., and Ross E.A. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 20 (1992) 301-306
2. Rosamond W., Flegal K., Friday G., et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
3. D'Agostino Sr. R.B., Grundy S., Sullivan L.M., and Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 286 (2001) 180-187
4. Kuller L.H., Arnold A.M., Psaty B.M., et al. 10-year follow-up of subclinical cardiovascular disease and risk of coronary heart disease in the Cardiovascular Health Study. Arch Intern Med 166 (2006) 71-78
5. McKie P.M., Rodeheffer R.J., Cataliotti A., et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension 47 (2006) 874-880
6. Kistorp C., Raymond I., Pedersen F., Gustafsson F., Faber J., and Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293 (2005) 1609-1616
7. Olsen M.H., Hansen T.W., Christensen M.K., et al. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J 28 (2007) 1374-1381
8. Wang T.J., Larson M.G., Levy D., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350 (2004) 655-663
9. Zethelius B., Berglund L., Sundstrom J., et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 358 (2008) 2107-2116
10. Wang T.J., Gona P., Larson M.G., et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355 (2006) 2631-2639
11. Fried L.P., Borhani N.O., Enright P., et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1 (1991) 263-276
12. Psaty B.M., Kuller L.H., Bild D., et al. Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. Ann Epidemiol 5 (1995) 270-277
13. Ordonez-Llanos J., Collinson P.O., and Christenson R.H. Amino-terminal pro-B-type natriuretic peptide: analytic considerations. Am J Cardiol 101 (2008) 9-15
14. Ives D.G., Fitzpatrick A.L., Bild D.E., et al. Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. Ann Epidemiol 5 (1995) 278-285
15. Rautaharju P.M., Manolio T.A., Siscovick D., et al., Cardiovascular Health Study Collaborative Research Group. Utility of new electrocardiographic models for left ventricular mass in older adults. Hypertension 28 (1996) 8-15
16. Furberg C.D., Manolio T.A., Psaty B.M., et al., Cardiovascular Health Study Collaborative Research Group. Major electrocardiographic abnormalities in persons aged 65 years and older (the Cardiovascular Health Study). Am J Cardiol 69 (1992) 1329-1335
17. Gottdiener J.S., Arnold A.M., Aurigemma G.P., et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 35 (2000) 1628-1637
18. Third report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Risk Assessment Tool for Estimating Your 10-Year Risk of Having a Heart Attack (2009). http://hp2010.nhlbihin.net/atpiii/calculator.asp Accessed February 17, 2009
19. Schou M., Gustafsson F., Nielsen P.H., Madsen L.H., Kjaer A., and Hildebrandt P.R. Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. Eur J Heart Fail 9 (2007) 68-74
20. Krantz D.S., Kop W.J., Gabbay F.H., et al. Circadian variation of ambulatory myocardial ischemia. Triggering by daily activities and evidence for an endogenous circadian component. Circulation 93 (1996) 1364-1371
21. Heagerty P.J., Lumley T., and Pepe M.S. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56 (2000) 337-344
22. Pencina M.J., D'Agostino Sr. R.B., D'Agostino Jr. R.B., and Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27 (2008) 157-172 discussion 207-12
23. The R Project for Statistical Computing. http://www.r-project.org Accessed December 22, 2009
24. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
25. Shlipak M.G., Fried L.F., Cushman M., et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 293 (2005) 1737-1745
26. Konstam M.A. Natriuretic peptides and cardiovascular events: more than a stretch. JAMA 297 (2007) 212-214
27. Morrow D.A., de Lemos J.A., Blazing M.A., et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA 294 (2005) 2866-2871
28. Anand I.S., Fisher L.D., Chiang Y.T., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 (2003) 1278-1283
29. Gregg E.W., Cauley J.A., Stone K., et al. Relationship of changes in physical activity and mortality among older women. JAMA 289 (2003) 2379-2386
30. Schocken D.D., Benjamin E.J., Fonarow G.C., et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 117 (2008) 2544-2565
31. Pfisterer M., Buser P., Rickli H., et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 301 (2009) 383-392
32. Fried L.P., Kronmal R.A., Newman A.B., et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA 279 (1998) 585-592
33. Cauliez B., Guignery J., Marinier S., Mariau I., and Lavoinne A. Two-year stability of NT-proBNP in frozen samples using the Roche Elecsys system. Ann Clin Biochem 45 (2008) 318-319
34. Schou M., Gustafsson F., Kjaer A., and Hildebrandt P.R. Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. Eur Heart J 28 (2007) 177-182